Share This Author
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Detailed genetic and histological analysis of 37 patients with drug-resistant non–small cell lung cancers carrying EGFR mutations provides new insights into the shifting sands of drug resistance evolution in lung cancers and suggests that serial biopsies may be essential in the quest to reverse or even prevent the development ofdrug resistance.
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
Crizotinib is superior to standard chemotherapy in patients with previously treated, advanced non-small-cell lung cancer with ALK rearrangement and greater improvement in global quality of life with crizotinIB than with chemotherapy.
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
The inhibition of ALK in lung tumors with the ALK rearrangement resulted in tumor shrinkage or stable disease in most patients, and the drug resulted in grade 1 or 2 gastrointestinal side effects.
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
- A. Shaw, B. Yeap, A. Iafrate
- Medicine, BiologyJournal of clinical oncology : official journal…
- 10 September 2009
EML4-ALK defines a molecular subset of NSCLC with distinct clinical characteristics and patients who harbor this mutation do not benefit from EGFR TKIs and should be directed to trials of ALK-targeted agents.
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Findings from a series of lung cancer patients with acquired resistance to the ALK TKI crizotinib reinforce the need to tailor therapeutic strategies to the specific underlying drug resistance mechanisms in the tumors to improve clinical outcomes.
Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer
As compared with crizotinib, alectinib showed superior efficacy and lower toxicity in primary treatment of ALK‐positive NSCLC and independent review committee–assessed progression‐free survival were consistent with those for the primary end point.
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
The first preclinical evaluation of the next-generation ALK TKI, ceritinib (LDK378), in the setting of crizotinib resistance demonstrates that ceritInib can overcome crizotib resistance, consistent with clinical data showing marked efficacy of cerit inib in patients with crizotonib-resistant disease.